Cibus (CBUS)

• Market cap: $70.1M
• 1 day: -5.36%
• 5 days: -34.73%
• 1 month: -33.25%
• 3 months: -33.75%
• 6 months: -72.54%
• Year to date: -85.57%
• 1 year: -82.78%
• 5 years: -96.25%
• 10 years: -97.64%
• Sector: Materials
• Industry: Agricultural Chemicals

About: Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.

Employees: 183

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

320% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 5

33% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 12

8% more funds holding

Funds holding: 53 [Q2] → 57 (+4) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]

2.09% less ownership

Funds ownership: 36.2% [Q2] → 34.1% (-2.09%) [Q3]

64% less capital invested

Capital invested by funds: $81.6M [Q2] → $29.1M (-$52.6M) [Q3]

99% less call options, than puts

Call options by funds: $1K | Put options by funds: $75K

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $20 655% upside
• Avg. target: $23 762% upside
• High target: $25 843% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Amit Dayal 39% 1-year accuracy 44 / 112 met price target	843% upside $25	Buy Reiterated	11 Nov 2024
Canaccord Genuity Austin Moeller 46% 1-year accuracy 18 / 39 met price target	655% upside $20	Buy Maintained	22 Oct 2024
Alliance Global Partners Matthew Venezia 0% 1-year accuracy 0 / 2 met price target	787% upside $24	Buy Maintained	24 Sept 2024